Profiel
Espen Daae is currently the Chairman at Biochromix AB and Director at Voksenåsen AS.
He is also the Portfolio Manager & Business Developer at Ferd sosiale Entreprenører AS since 2015.
Previously, he worked as a Director at Neomed Management (Jersey) Ltd.
and as a Non-Executive Director at BioChromix Pharma AB.
Actieve functies van Espen Daae
Bedrijven | Functie | Begin |
---|---|---|
Biochromix AB
Biochromix AB Medical SpecialtiesHealth Technology BioChromix AB manufactures diagnostic products. It is a company in the life science arena that develops and commercializes products for early stage diagnostics of Alzheimer's disease (AD) and identification of biomarkers associated to AD. The firm’s methods are based on their novel and patented Luminescent Conjugated Polymer (LCP) molecules. The company is headquartered in Solna, Sweden. | Voorzitter | 15-06-2011 |
Ferd sosiale Entreprenører AS | Private Equity Investor | 01-08-2015 |
Voksenåsen AS
Voksenåsen AS Hotels/Resorts/Cruise linesConsumer Services Voksenåsen AS is a private company based in Oslo, Norway. The company operates as a conference hotel and center for Norwegian-Swedish cooperation. Voksenåsen is Norway's national gift to Sweden and is a joint Swedish-Norwegian initiative aimed at promoting Nordic unity and social understanding through cultural, social, and linguistic events. The CEO of the company is Maria af Klinteberg Herresthal. | Directeur/Bestuurslid | - |
Eerdere bekende functies van Espen Daae
Bedrijven | Functie | Einde |
---|---|---|
Neomed Management (Jersey) Ltd.
Neomed Management (Jersey) Ltd. Investment ManagersFinance Neomed Management (Jersey) Ltd. is an investment firm invests in innovative healthcare and life science companies. The company is headquartered in St. Helier, the United Kingdom. | Directeur/Bestuurslid | - |
BioChromix Pharma AB
BioChromix Pharma AB Miscellaneous Commercial ServicesCommercial Services BioChromix Pharma AB was founded as a subsidiary to BioChromix AB. The Company is a pharmaceutical company active in research and development of novel treatments for neurodegenerative disorders based on its proprietary technology for therapeutics. Current research and development is focused on the indication area of Alzheimer's disease but the prion diseases, Parkinson's disease and other neurodegenerative disorders might also be included in the future. BioChromix Pharma is performing pre-clinical development but is looking to reach the clinical phase within the coming years. Alzheimer's disease is the most common neurodegenerative disease, affecting around 25 million people and the costs associated with AD are tremendous. At the moment, there are no efficient treatments for AD but there are clinical trials are ongoing and some are focused at reducing the levels of the neurotoxic Aß peptide. The portfolio of the company includes a number of newly discovered lead compounds that are under investigation. | Directeur/Bestuurslid | - |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Bedrijven in privébezit | 5 |
---|---|
Neomed Management (Jersey) Ltd.
Neomed Management (Jersey) Ltd. Investment ManagersFinance Neomed Management (Jersey) Ltd. is an investment firm invests in innovative healthcare and life science companies. The company is headquartered in St. Helier, the United Kingdom. | Finance |
Biochromix AB
Biochromix AB Medical SpecialtiesHealth Technology BioChromix AB manufactures diagnostic products. It is a company in the life science arena that develops and commercializes products for early stage diagnostics of Alzheimer's disease (AD) and identification of biomarkers associated to AD. The firm’s methods are based on their novel and patented Luminescent Conjugated Polymer (LCP) molecules. The company is headquartered in Solna, Sweden. | Health Technology |
BioChromix Pharma AB
BioChromix Pharma AB Miscellaneous Commercial ServicesCommercial Services BioChromix Pharma AB was founded as a subsidiary to BioChromix AB. The Company is a pharmaceutical company active in research and development of novel treatments for neurodegenerative disorders based on its proprietary technology for therapeutics. Current research and development is focused on the indication area of Alzheimer's disease but the prion diseases, Parkinson's disease and other neurodegenerative disorders might also be included in the future. BioChromix Pharma is performing pre-clinical development but is looking to reach the clinical phase within the coming years. Alzheimer's disease is the most common neurodegenerative disease, affecting around 25 million people and the costs associated with AD are tremendous. At the moment, there are no efficient treatments for AD but there are clinical trials are ongoing and some are focused at reducing the levels of the neurotoxic Aß peptide. The portfolio of the company includes a number of newly discovered lead compounds that are under investigation. | Commercial Services |
Ferd sosiale Entreprenører AS | Finance |
Voksenåsen AS
Voksenåsen AS Hotels/Resorts/Cruise linesConsumer Services Voksenåsen AS is a private company based in Oslo, Norway. The company operates as a conference hotel and center for Norwegian-Swedish cooperation. Voksenåsen is Norway's national gift to Sweden and is a joint Swedish-Norwegian initiative aimed at promoting Nordic unity and social understanding through cultural, social, and linguistic events. The CEO of the company is Maria af Klinteberg Herresthal. | Consumer Services |